List of Excipients in Branded Drug DIVIGEL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	DIVIGEL	estradiol	54868-6056	ALCOHOL
Physicians Total Care Inc	DIVIGEL	estradiol	54868-6056	CARBOMER HOMOPOLYMER TYPE C
Physicians Total Care Inc	DIVIGEL	estradiol	54868-6056	PROPYLENE GLYCOL

Last updated: August 9, 2026

Divigel is a 0.1% estradiol hydroalcoholic gel with a relatively simple excipient system: ethanol, propylene glycol, carbomer 974P, and purified water. Its commercial vulnerability is tied to generic substitution, limited formulation complexity, and the absence of a clearly differentiated delivery device. The strongest excipient opportunities are alcohol reduction, improved skin tolerability, transfer control, sachet or pump redesign, and new dosage strengths that can support separate regulatory protection.

DIVIGEL Excipient Strategy, Patent Position, and Commercial Opportunities

What is Divigel and how does its formulation work?

Divigel is a topical estradiol product used for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The product contains 1 mg of estradiol per gram of gel, equivalent to a 0.1% w/w concentration. It is applied once daily to the skin of the upper thigh, with alternating thighs recommended in the prescribing information.[1]

The formulation uses a conventional hydroalcoholic transdermal platform:

Component	Function in Divigel
Estradiol	Active pharmaceutical ingredient
Ethanol	Volatile solvent and penetration-promoting vehicle
Propylene glycol	Cosolvent, humectant, and skin-penetration aid
Carbomer 974P	Gelling and viscosity-control polymer
Purified water	Vehicle

Divigel is supplied in single-use packets. The packet format controls dose presentation and reduces repeated container opening, but it also creates manufacturing, packaging, and user-acceptance constraints.[1]

The formulation’s value proposition is based on systemic estradiol delivery through the skin. Compared with oral estradiol, transdermal delivery can avoid first-pass hepatic metabolism and is associated with lower exposure to certain hepatic effects. The product still carries the class risks and boxed-warning considerations applicable to estrogen therapy.[1]

What excipients are used in Divigel?

The core excipient system is publicly disclosed in the FDA prescribing information and product labeling. Divigel contains carbomer 974P, ethanol, propylene glycol, and purified water as inactive ingredients.[1,2]

Ethanol

Ethanol performs two important technical functions. It dissolves or helps solubilize estradiol and supports rapid evaporation after application. Evaporation leaves a concentrated drug residue on the skin, while the transient solvent environment can improve drug partitioning into the stratum corneum.

Ethanol also creates commercial liabilities:

• Stinging or burning on compromised skin.
• Dryness and irritation with repeated use.
• Odor during application.
• Flammability during manufacturing and storage.
• Sensitivity to package seal integrity and solvent loss.
• Potential changes in dose uniformity if evaporation occurs before use.

A lower-ethanol or ethanol-free replacement would be commercially attractive, but it would require reoptimization of estradiol solubility, viscosity, drying behavior, permeation, microbial control, and bioequivalence.

Propylene glycol

Propylene glycol supports estradiol solubilization and can act as a penetration enhancer. It also helps retain water in the formulation and can influence gel spreadability.

Its risks are concentration-dependent skin irritation and variability in the sensory profile. Substitution with dipropylene glycol, polyethylene glycol, glycerol, pentylene glycol, or specialized transdermal solvents could create a differentiated formulation, but each substitution would require assessment of:

• Estradiol solubility.
• Flux across human skin.
• Lag time to systemic exposure.
• Residual tackiness.
• Drying time.
• Skin irritation and sensitization.
• Stability under accelerated and long-term conditions.

Carbomer 974P

Carbomer 974P gives the product its gel structure and controls viscosity. Carbomer selection affects spreading, packet emptying, dose recovery, adhesion to skin, and the rate at which the formulation dries.

A carbomer grade change may appear minor, but it can alter:

• Yield stress.
• Gel clarity.
• Neutralization requirements.
• Estradiol release.
• Applicator feel.
• Residual film formation.
• Batch-to-batch rheology.

Alternative polymers, including acrylates copolymers, hydroxypropyl cellulose, poloxamers, polycarbophil, and associative thickeners, could support improved sensory performance. The regulatory burden would depend on the extent of the change and its effect on drug release and pharmacokinetics.

What formulation patents protect Divigel?

Divigel’s principal regulatory protection originated from its approved estradiol gel formulation and associated product development. The commercial opportunity today is more likely to arise from improvements around the formulation, package, dose presentation, or administration method than from broad exclusivity over estradiol gel itself.

The relevant intellectual-property categories are:

IP category	Potential scope	Commercial importance
Composition patents	Estradiol, solvent, polymer, and excipient ratios	Protects the formulation if claims remain enforceable
Method-of-use patents	Dosing regimens, application sites, or symptom treatment	Can delay or complicate generic use claims
Manufacturing patents	Mixing order, deaeration, filling, and solvent-loss controls	Creates process barriers but may be difficult to enforce
Packaging patents	Unit-dose sachets, dose-metering systems, and barrier structures	Supports lifecycle management
Device patents	Pumps, applicators, dose counters, and transfer-control systems	Can differentiate the product from a simple generic gel
Trade secrets	Mixing conditions, filling parameters, and stability controls	Useful where public patent disclosure is unattractive

A current Orange Book review should distinguish between patents listed for the reference product and patents covering later improvements. FDA Orange Book listings do not capture every potentially relevant patent, particularly manufacturing, packaging, formulation-process, and foreign rights.[3]

For Divigel, a generic applicant may challenge listed patents through a Paragraph IV certification if relevant patents remain listed. If no blocking patent remains listed or enforceable, the major barriers shift to formulation equivalence, manufacturing validation, and commercial scale.

What is the Orange Book status of Divigel?

Divigel is an FDA-approved prescription drug marketed under NDA 022038. The FDA-approved product is estradiol topical gel at 0.1% strength.[1,3]

The Orange Book analysis should address four questions:

1. Whether NDA 022038 has active patent listings.
2. Whether any listed patent dates have expired.
3. Whether a generic estradiol gel has been approved with a therapeutic-equivalence rating.
4. Whether an approved generic is subject to a 30-month stay arising from Paragraph IV litigation.

The existence of an Orange Book listing does not itself establish a durable commercial barrier. A listed patent may be expired, challenged, disclaimed, licensed, or limited to a narrow claim. A generic applicant can also file a Paragraph III certification agreeing to wait until patent expiration rather than challenge validity.

For lifecycle planning, the key distinction is between:

• Patent protection for the original gel composition.
• Regulatory exclusivity linked to the initial approval.
• Later patents covering formulation or packaging changes.
• Trademark and brand-recognition protection.
• Practical barriers created by manufacturing and distribution.

Divigel’s original FDA approval dates back to the 2000s. Any original five-year new-chemical-entity exclusivity has expired. The commercial analysis therefore depends primarily on patent status, generic approval, market access, and formulation differentiation rather than FDA exclusivity.[3,4]

When does Divigel lose exclusivity?

Divigel’s original regulatory exclusivity has expired. The timing of generic entry depends on the surviving patent estate and whether a generic applicant obtains approval for the same dosage form and strength.

A simplified exclusivity timeline is:

Milestone	Approximate status
Initial U.S. approval	2007
Five-year NCE exclusivity	Expired
Original product patent term	Dependent on the specific listed patent and patent-term adjustment
Paragraph IV risk	Dependent on active Orange Book listings
Generic entry	Possible after applicable patent and regulatory barriers
Lifecycle patents	May extend protection only for the claimed improvement

The most important commercial question is not simply the expiration date of an original patent. It is whether the remaining claims cover the product that a generic applicant intends to market. A narrow claim to a particular excipient ratio may not block a product using a different carbomer grade or solvent system.

What generic entry risks exist for Divigel?

Generic risk is material because the product has a relatively small molecule, a well-defined active ingredient, and a nonbiologic dosage form. The key technical issue is demonstrating equivalence for a topical product whose performance depends on formulation and skin delivery.

A generic applicant may pursue an abbreviated new drug application if it can establish pharmaceutical equivalence and bioequivalence under FDA requirements. For topical products, the relevant evidence may include comparative clinical endpoint data, pharmacokinetic studies, in vitro release testing, or other product-specific methods identified by FDA.[5]

Generic entry risks include:

• Price erosion from an AB-rated generic.
• Payer substitution at the pharmacy level.
• Loss of formulary preference.
• Wholesale and retail inventory conversion.
• Greater scrutiny of product availability and packet count.
• Substitution by other estradiol delivery systems.
• Use of authorized generic pricing to defend share.

The most exposed portion of the business is standard 0.1% estradiol gel without a differentiated applicator, low-transfer claim, or superior tolerability profile.

Which excipient strategies could create commercial opportunities?

1. Low-alcohol or alcohol-free estradiol gel

An alcohol-reduced formulation could address dryness, burning, and odor. The technical challenge is maintaining estradiol solubility and adequate transdermal flux without relying on ethanol.

Possible approaches include:

• Mixed glycol systems.
• Solubilizing surfactants.
• Cyclodextrin complexes.
• Lipid-based microemulsions.
• Volatile nonethanol solvents.
• Polymer systems that maintain drug activity at the skin interface.

A successful platform could support a new composition patent and product repositioning around tolerability. It would need head-to-head evidence showing acceptable systemic exposure and comparable symptom control.

2. Reduced-transfer formulation

Estradiol gels can create concerns about secondary exposure when untreated skin contacts another person. A formulation designed to dry rapidly and leave less transferable residue could support a meaningful commercial claim.

Excipient levers include:

• Faster solvent evaporation.
• Film-forming polymers.
• Lower wet tack.
• Controlled skin adhesion.
• Reduced residual surface drug.
• Polymer-drug interactions that limit transfer after drying.

The strongest evidence would combine in vitro transfer testing, standardized contact studies, and clinical-use data.

3. Improved skin tolerability

A formulation that reduces stinging and dermatitis could compete against both generic estradiol gel and other estrogen delivery systems. Strategies may include:

• Lower ethanol concentration.
• Alternative pH adjustment.
• Reduced propylene glycol exposure.
• Skin-conditioning excipients.
• Lower residue after drying.
• Occlusion-resistant polymer systems.

Any soothing or moisturizing excipient must be evaluated for its effect on estradiol absorption. A humectant that improves comfort may also increase hydration of the stratum corneum and change systemic exposure.

4. Dose-strength and titration products

Divigel is available in multiple packet strengths in certain markets, allowing individualized dosing. A more precise dosing platform could reduce waste and improve titration.

Potential products include:

• Metered-dose pumps.
• Multi-dose airless containers.
• Unit-dose sachets with improved emptying.
• Low-dose initiation packets.
• Dose-counter devices.
• Combination starter and maintenance packs.

A pump can create a more convenient user experience, but it introduces dose-delivery validation, priming requirements, residual-volume issues, and container-closure testing.

5. Preservative-free and microbiologically robust packaging

A single-use package supports a preservative-free design. Further improvements could focus on low-residual-volume sachets, high-barrier laminates, and packaging that minimizes ethanol loss.

Manufacturing and packaging IP may cover:

• Heat-seal window and seal geometry.
• Solvent-resistant laminate structures.
• Filling temperature and deaeration.
• Low-shear mixing.
• Headspace control.
• Sachet opening design.

These rights may not prevent all generic competition, but they can support differentiated products and create manufacturing know-how that is difficult to replicate quickly.

How does Divigel compare with competing estradiol products?

Product type	Main excipient or delivery issue	Competitive position
Divigel-type estradiol gel	Ethanol evaporation, skin transfer, packet handling	Simple platform with generic exposure
Estradiol gel in a pump	Metered dosing and convenience	Stronger device differentiation
Estradiol spray	Rapid application and transfer concerns	Different sensory and adherence profile
Estradiol patch	Adhesion, skin reaction, visible device	No daily gel application
Vaginal estradiol products	Local delivery and lower systemic exposure	Different clinical use and regulatory positioning
Oral estradiol	First-pass metabolism and daily tablet use	Lower manufacturing complexity

Divigel competes most directly with other systemic transdermal estradiol products. Its opportunity is strongest where patients prefer a nonpatch, nonoral option and where the product can reduce application inconvenience or skin-transfer concerns.

What regulatory pathway applies to a new Divigel formulation?

A reformulated estradiol gel could require an NDA under section 505(b)(2), an ANDA, or a supplemental application, depending on the relationship to the reference product and the proposed claims.[4,5]

A 505(b)(2) pathway may be appropriate for a product that relies partly on existing estradiol safety and efficacy information but differs in formulation, dosage form, strength, or delivery system. This route can support a differentiated product while avoiding a full independent development program.

An ANDA is more appropriate when the product is intended to be therapeutically equivalent to the reference product. A formulation that changes excipients but preserves the required equivalence profile may still qualify, but the burden is product-specific.

The most valuable development data would include:

• Estradiol assay and degradation profile.
• Impurity and residual-solvent characterization.
• Viscosity and rheology.
• In vitro drug release.
• Skin permeation and deposition.
• Comparative pharmacokinetics.
• Adhesion and transfer testing.
• Irritation and sensitization.
• Container-closure integrity.
• In-use stability.
• Dose uniformity across the package life.

FDA’s topical-product guidance emphasizes the importance of Q1, Q2, and Q3 characterization, meaning qualitative composition, quantitative composition, and structural or physical similarity where applicable.[5]

What manufacturing and IP barriers matter most?

The largest technical barriers are not the basic selection of ethanol, propylene glycol, and carbomer. They are process controls that maintain uniform estradiol distribution and solvent content.

Critical manufacturing variables include:

• Order of excipient addition.
• Polymer hydration time.
• Shear rate.
• Neutralization endpoint.
• Estradiol dissolution temperature.
• Deaeration.
• Filling speed.
• Sachet seal integrity.
• Solvent-loss control.
• Bulk hold time.

Estradiol is used at a low concentration relative to the gel vehicle. Small deviations in mixing or filling can create dose-uniformity problems. Carbomer hydration and neutralization can also produce large rheology differences between batches.

A defensible patent strategy should claim a specific combination of:

• Estradiol concentration.
• Solvent system.
• Polymer grade or polymer ratio.
• Viscosity range.
• Drying time.
• Transfer reduction.
• Skin-flux profile.
• Package configuration.

Broad claims to an estradiol gel are more vulnerable to prior-art and obviousness challenges. Narrow claims tied to measurable performance attributes may be more commercially useful if the product demonstrates a clear advantage.

Which companies are positioned to challenge or compete with Divigel?

Competition can arise from three groups:

1. Generic pharmaceutical companies developing estradiol gel equivalents.
2. Branded hormone-therapy companies marketing alternative transdermal systems.
3. Specialty women’s-health companies licensing improved formulations or devices.

Potential counterparties for licensing include:

• Companies with topical semisolid manufacturing capacity.
• Developers of transdermal delivery polymers.
• Packaging suppliers with solvent-resistant unit-dose systems.
• Women’s-health companies with payer and gynecology channels.
• Generic manufacturers seeking a differentiated 505(b)(2) product.

A licensing package would be most attractive if it combines formulation know-how, human skin-permeation data, a validated package, and an enforceable patent position. A raw excipient substitution without comparative clinical or pharmacokinetic data would have limited transaction value.

What is the revenue exposure from generic entry?

Revenue exposure depends on brand share, payer control, generic substitution, and the availability of alternative estradiol products. A standard gel can experience rapid price compression after an AB-rated generic launch, particularly where pharmacy benefit managers impose automatic substitution.

A company managing Divigel should model three launch scenarios:

Scenario	Commercial effect
No approved generic	Brand retains pricing and channel control
One AB-rated generic	Rapid price erosion and pharmacy substitution
Multiple generics	Steep price decline, tender-driven purchasing, lower brand volume

The highest-value defense is usually a differentiated product with a distinct dosage form, delivery device, or clinically supported tolerability advantage. Patent litigation alone may delay entry but does not preserve long-term pricing if the underlying product remains undifferentiated.

Key Takeaways

• Divigel uses a simple hydroalcoholic system based on ethanol, propylene glycol, carbomer 974P, and purified water.
• The principal formulation opportunity is to reduce alcohol-related irritation while preserving estradiol solubility and transdermal delivery.
• Transfer reduction, rapid drying, better sachets, and metered-dose devices offer stronger lifecycle-management potential than minor excipient substitutions.
• Original regulatory exclusivity has expired, so commercial protection depends on active patents, market access, formulation differentiation, and manufacturing execution.
• Generic entry risk is significant for an undifferentiated 0.1% estradiol gel.
• A 505(b)(2) strategy may provide a practical route for a lower-transfer, alcohol-reduced, or device-enabled product.
• The strongest patent claims would link excipient composition to measurable performance, such as skin flux, drying time, transfer reduction, or dose uniformity.
• Manufacturing know-how around carbomer hydration, solvent control, deaeration, and sachet filling can be commercially important even when it is not publicly disclosed.

FAQs

Can ethanol be removed from Divigel without changing estradiol absorption?

Not reliably. Ethanol contributes to estradiol solubility, drying, and skin penetration. Removing it would require a new solvent and polymer system, followed by comparative permeation, pharmacokinetic, stability, and irritation testing.

Is propylene glycol essential to Divigel?

No. It is functionally important but not necessarily irreplaceable. A substitute would need to preserve estradiol solubility, delivery, gel performance, and tolerability.

Could a new Divigel pump receive separate patent protection?

Yes. A pump, dose-metering mechanism, container, or transfer-control system may support separate patent claims if it has a novel structure or produces a measurable delivery advantage.

Are biosimilars relevant to Divigel?

No. Divigel contains estradiol, a small-molecule active ingredient. Competitive products would generally be generics or reformulated small-molecule products, not biosimilars.

What is the most commercially valuable Divigel improvement?

A lower-transfer, low-irritation formulation with precise metered dosing would likely have the strongest commercial profile because it addresses patient experience, caregiver exposure concerns, and generic substitution at the same time.

References

1. U.S. Food and Drug Administration. (2019). Divigel (estradiol gel) prescribing information. Vertical Pharmaceuticals, LLC.

2. National Library of Medicine. (n.d.). DailyMed: Divigel, estradiol gel. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.

5. U.S. Food and Drug Administration. (2022). Draft guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. FDA.